The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Analyst Andrew Berens of Leerink Partners maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of ...
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...
The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...
Tokyo: Daichi Sankyo has announced that DATROWAY (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the ...
(RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab deruxtecan) has been approved in the United States for ...